.jpg "Kitov Pharmceuticals (NASDAQ: KTOV)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kitov Pharmceuticals (NASDAQ: KTOV), Cytori Therap (NASDAQ: CYTX) and Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) with bullish sentiments.
Kitov Pharmceuticals (NASDAQ: KTOV)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Kitov Pharmceuticals (NASDAQ: KTOV) today and set a price target of $10. The company’s shares closed on Friday at $2.40.
Selvaraju noted:
“We remind investors that KIT-302, a combination drug intended to simultaneously treat osteoarthritis-related pain and hypertension (a common side effect of stand-alone drugs that treat osteoarthritis-related pain), is comprised of two FDA-approved drugs, celecoxib (Celebrex®), a non-steroidal anti-inflammatory COX-2 inhibitor (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure. The approval decision date for KIT-302 is May 31, 2018. We consider the China licensing transaction to be evidence that Kitov is continuing to pursue initiatives to optimize the commercial value of its lead candidate, and remain confident that Consensi should be approved by the end of this month. We reiterate our Buy rating and 12-month price target of $10.00 per share.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.1% and a 37.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Kitov Pharmceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $10.
See today’s analyst top recommended stocks >>
Cytori Therap (NASDAQ: CYTX)
H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Cytori Therap (NASDAQ: CYTX) today and set a price target of $4. The company’s shares closed on Friday at $0.28, close to its 52-week low of $0.22.
Kolbert commented:
“We learned of real differences between various versions of this drug, which have been demonstrated in studies. It turns out that as liposomal formulations are complex, not all versions are the same. In fact, results of a clinical trial demonstrated the superiority of Caelyx/Doxil to Lipodox. The good news is that Cytori has shown bioequivalence to the reference standard in Europe, which is Caelyx. We note the U.S. reference standard is actually Sun Pharma’s (Bombay #524715: not rated), Lipodox, which today appears to be inferior. This raises a question about whether the FDA may insist that the first U.S. generic use Lipodox as the reference standard, or could it accept Cytori’s ATI-0918 as it is based on Caelyx, which appears superior to Lipodox.”
According to TipRanks.com, Kolbert has 0 stars on 0-5 star ranking scale with an average return of -4.9% and a 38.1% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Sonoma Pharmaceuticals Inc, and Cellular Biomedicine Group.
Currently, the analyst consensus on Cytori Therap is Strong Buy and the average price target is $2.23, representing a 710.3% upside.
In a report issued on April 30, Maxim Group also maintained a Buy rating on the stock with a $2 price target.
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) today and set a price target of $1.25. The company’s shares closed on Friday at $0.49, close to its 52-week low of $0.48.
Ramakanth observed:
“We have adjusted our financial projections to account for the reported financial results. For 2018, we currently project no revenues and a net loss of $0.43 per share. We note the company reported cash and cash equivalents of $16.2M, which we believe is sufficient to fund operations through 2Q19.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 5.3% and a 39.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Eleven Biotherapeutics, IntelGenx Technologies, and Trillium Therapeutics.
Diffusion Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $1.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
